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Abstract
The human pathogen Mycobacterium tuberculosis is the causative agent of pulmonary tuberculosis (TB), a disease with high
worldwide mortality rates. Current treatment programs are under significant threat from multi-drug and extensively-drug
resistant strains of M. tuberculosis, and it is essential to identify new inhibitors and their targets. We generated spontaneous
resistant mutants in Mycobacterium bovis BCG in the presence of 106 the minimum inhibitory concentration (MIC) of
compound 1, a previously identified potent inhibitor of mycobacterial growth in culture. Whole genome sequencing of two
resistant mutants revealed in one case a single nucleotide polymorphism in the gene aspS at 535GAC.535AAC (D179N),
while in the second mutant a single nucleotide polymorphism was identified upstream of the aspS promoter region. We
probed whole cell target engagement by overexpressing either M. bovis BCG aspS or Mycobacterium smegmatis aspS, which
resulted in a ten-fold and greater than ten-fold increase, respectively, of the MIC against compound 1. To analyse the impact
of inhibitor 1 on M. tuberculosis AspS (Mt-AspS) activity we over-expressed, purified and characterised the kinetics of this
enzyme using a robust tRNA-independent assay adapted to a high-throughput screening format. Finally, to aid hit-to-lead
optimization, the crystal structure of apo M. smegmatis AspS was determined to a resolution of 2.4 A˚.
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Introduction
The causative agent of tuberculosis (TB), Mycobacterium
tuberculosis, accounts for nearly 1.4 million fatalities worldwide,
with an incidence rate of 8.8 million cases per annum [1–3]. This
situation is compounded due to co-infection with the Human
Immunodeficiency Virus (HIV), and the rise in infections with
multi-drug resistant TB (MDR-TB) [4], extensively-drug resistant
TB (XDR-TB) and totally-drug resistant (TDR-TB) strains [5].
High Throughput Screening (HTS) of extensive compound
libraries now enables researchers to focus on whole cell phenotypic
profiling of hits with bactericidal or bacteriostatic activity rather
than limiting efforts to single-enzyme methodologies [6–11]. In
this regard, the discovery of the inhibitor diarylquinoline TMC207
(Bedaquiline) was a notable success where HTS was coupled with
the use of whole genome sequencing (WGS) of spontaneous
resistant mutants to identify the cellular target, M. tuberculosis
ATP synthase [12–15]. In addition, mode of action studies of other
anti-TB compounds, such as SQ109, BM212, adamantyl ureas,
benzimidazole, BTZ, TCA, and imidazo[1,2-a]pyridine related
derivatives [16–24] have established their cellular targets by WGS
of spontaneous resistant mutants generated against these com-
pounds [25].
Using this established strategy of target deconvolution, M.
tuberculosis aspartyl tRNA synthetase aspS has been recently
identified as the cellular target of compound 1 (Figure 1) [26].
The aspartyl tRNA synthetase (aspS) belongs to a group of twenty
aminoacyl tRNA synthetases (aaRSs) which are divided into two
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classes, class I and class II, which are differentiated by their
aminoacylation domains [27]. Aminoacylation by aaRSs occurs in
a two-step process: (i) activation of the amino acid with ATP
resulting in the formation of an aminoacyl-adenylate, and (ii)
aminoacylation of the tRNA by the aminoacyl adenylate [28].
Several prokaryotes including mycobacteria do not contain the
open reading frame encoding the asparagine tRNA synthetase and
the glutamine tRNA synthetase [29,30]. AspS and Glutamyl
tRNA synthetase (GluS) play the role of a non-discriminating
amino acyl tRNA synthetase and could also acylate tRNAAsn and
tRNAGln with Aspartate and Glutamate respectively [29]. The
eighteen aaRSs of mycobacteria are essential for protein synthesis
and represent viable targets for the development of new
therapeutics [29,31]. Indeed, several naturally occurring antimi-
crobials have been shown to be specific aaRSs inhibitors [32].
Among them are Microcin C (McC) produced by Enterobacte-
riaceae, which inhibits translation by preventing aminoacylation of
tRNAAsp by AspS and Tobramycin, an aminoglycoside compet-
itive inhibitor with respect to tRNAAsp [33–35]. McC functions
through a trojan horse mechanism because it enters the bacterial
membrane as a prodrug by facilitated transport, undergoes
processing by cellular aminopeptidases and releases a toxic moiety
called aspartyl adenylate which inhibits AspS [33,36]. Herein, we
report the detailed biochemical characterization of the M.
tuberculosis aspartyl-tRNA synthetase AspS and we report the
2.4 A˚-resolution crystal structure of the M. smegmatis homologue.
Materials and Methods
Ethics Statement
All experiments were approved by the University of Birming-
ham and Diseases of the Developing World (DDW-GSK) ethical
committee where required and there are no ethical issues to
report.
Chemicals & Materials
Phusion DNA polymerase, DNA restriction enzymes and
T4DNA ligase, One Taq hot start 2X master mix RT-PCR kit,
and RNase free DNase set were procured from New England
Biolabs (NEB). RNeasy mini kit was obtained from Qiagen. Trizol
reagent and Turbo DNA-free kit were obtained from Life
Technologies. b, c adenylyl imidodiphosphate lithium salt
(ADPNP), Adenylylmethylenediphosphonate disodium salt
(ADPCP), ATP, NADP+, tetrasodium pyrophosphate, and
CHAPS were purchased from Sigma Aldrich (St. Louis, MO,
USA). Compounds 1 (F1673-0402) and 2 (6632725) (Figure 1)
were purchased from Lifechemicals.com and Chembridge,
respectively and were used as such. A mixture of yeast hexokinase
and Leuconostoc mesenteroides glucose-6-phosphate dehydroge-
nase was obtained from Roche Applied Science, Mannheim,
Germany. Oligonucleotide primers were synthesised by MWG
Eurofins, Germany.
Generation and WGS of spontaneous resistant mutants,
cloning of M. bovis BCG and M. smegmatis aspS in
pMV261 and MIC determination of compound 1 and 2
Spontaneous resistant mutants of M. bovis BCG were generated
against compound 1 at 106MIC (MIC = 2.6 mM) by plating 108
cells on solid media as described previously [23,26]. Purified
genomic DNA from each mutant (two) and the parental strain
were prepared for sequencing using the Illumina Nextera DNA
Sample Preparation Kit (Illumina, Great Chesterford, UK).
Genomic DNA (25 ng) was simultaneously fragmented and tagged
with adapters using the Nextera transposome. The tagged
fragments were amplified by limited-cycle PCR, incorporating
Illumina sequencing primer sequences and indices required for
cluster generation and sequencing. The DNA libraries were
purified using Agencourt AMPure XP beads (Beckman Coulter
Figure 1. Structures of compounds 1 and 2 used in this study.
doi:10.1371/journal.pone.0113568.g001
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Genomics, High Wycombe, UK) and quantified with Quant-iT
PicoGreen dsDNA kit (Life Technologies). The median fragment
size (420–575 bp) of the final libraries was determined on an
Agilent Technologies 2100 Bioanalyzer using a High Sensitivity
DNA chip. The libraries were diluted to 2 nM, combined and
denatured according to the MiSeq preparation guide. The
libraries were sequenced on a MiSeq Benchtop Sequencer using
the MiSeq Reagent Kit v2, 300 cycles. Reads were aligned to the
M. bovis BCG Pasteur 1173P2 reference genome sequence
(accession: NC_008769.1) using the Burrows-Wheeler Aligner
(BWA) version 0.6.1 in bwasw mode and default settings [37].
Putative variants were then detected using samtools mpileup
pipeline using default settings. The output was filtered with
VarScan v2.3.5 [38,39] to detect variants with an allele frequency
of greater or equal to 90% with more than five covering reads and
with a p-value of less than 0.005. The putative effect of SNPs on
coding sequences was determined using snpEff 2.0.5d [40].
M. bovis BCG aspS and M. smegmatis aspS were amplified by
PCR using the oligonucleotides shown in Table 1. PCR was
carried out using Phusion DNA polymerase and as per the
conditions recommended by the manufacturer. The PCR product
was digested with BamHI and HindIII and ligated into plasmid
pMV261 which was similarly cut and transformed into E. coli Top
10 cells. The sequences of the cloned constructs were confirmed by
sequencing. The plasmids were transformed by electroporation
into electrocompetent M. bovis BCG cells for MIC determination
against compounds 1 (F1673-0402, Lifechemicals.com) and 2
(6632725, Chembridge) (Figure 1), in comparison to an empty
pMV261 control, as reported previously [23,26].
Isolation and purification of total RNA, cDNA synthesis
and RT-PCR
The wild type M. bovis BCG, promoter up mutant and the
AspS mutant cultures (50 ml each) were grown until mid
logarithmic phase (A600 of 0.8) and the total RNA was extracted
from the pellet for cDNA synthesis using the RNA-Trizol protocol
as described [41,42]. The isolated RNA was purified using RNeasy
spin columns (Qiagen), digested with RNase free DNase (NEB)
and the RNA cleaned up using the RNeasy spin column to remove
DNase. The residual amount of genomic DNA contamination was
removed by treating the RNA again with Turbo DNA free kit
DNase (Life Technologies) and reagents removed using the same
kit to remove DNase and divalent cations from the RNA. The
purified RNA samples (600 ng each) were used as templates for
cDNA synthesis using the NEB kit as per manufacturers
instructions. Control reactions were set up without addition of
reverse transcriptase. M. bovis BCG aspS gene specific primers
were designed to amplify by RT-PCR the 200 bp intergenic
region. The oligos designed for RT-PCR are M. bovis BCG aspS
Left (59-39)CGATCTCCGAGGAAGTTCTG and M. bovis BCG
aspS Right (59-39) ACATACGGTGCCTGGAAGAC, respective-
ly. PCR was carried out as per the manufacturers instructions
using the master mix provided in the One Taq hot start 2X master
mix kit (NEB), M. bovis BCG aspS specific primers and the
synthesised cDNA as template. The RT-PCR cycling conditions
were programmed for 25, 30, 40 and 50 cycles, respectively, to get
sufficient yields of the 200 bp amplified product. The transcripts
(20 ml each) were analysed on a 2% agarose gel.
Cloning of M. tuberculosis and M. smegmatis aspS in
pET28b
The M. tuberculosis and M. smegmatis aspS were amplified by
PCR from M. tuberculosis H37Rv and M. smegmatis genomic
DNA, respectively, and cloned into pET28b to generate C-
terminally-tagged Histidine (His6) fusion proteins. The oligonu-
cleotide primers used for pET28b cloning are shown in Table 1.
The forward primer contains the NdeI restriction site and the
reverse primer contains the HindIII restriction site. The PCR
product was purified, digested with NdeI and HindIII and ligated
into the expression vector pET28b using NdeI and HindIII
restriction sites. Both the C-terminal His6 tagged constructs were
verified by sequencing.
Expression and purification of the C-terminally His6-
tagged Mt-AspS for activity assays
The pET28b-Mt-aspS construct with the C-terminal His6-tag
was transformed into E. coli C41 (DE3) cells for protein
expression. An overnight starter culture was prepared by
inoculating a single colony from a freshly transformed plate into
LB broth containing kanamycin (25 mg/ml). A 1% inoculum of
the starter culture was used to inoculate 1 L of LB broth
containing kanamycin (25 mg/ml), grown at 37uC until the
OD600 of 0.6 was attained, induced with 1 mM isopropyl-b-D-
thiogalactopyranoside (IPTG), and cultured at 16uC for 18 hours.
The harvested cells were resuspended in lysis buffer containing
20 mM Tris-HCl pH 8.0, 500 mM NaCl, 10% glycerol, 40 mM
imidazole, 1 mg/ml lysozyme and protease inhibitor tablet and
disrupted by sonication with eight cycles of 30 s pulses at 30 s
intervals. The crude lysate was clarified by centrifugation at
15,000 rpm for 45 minutes. The supernatant was loaded onto a
pre-packed Ni2+ Sepharose HisTrap high performance column
(GE Healthcare), which was equilibrated with buffer A (lysis buffer
without lysozyme and protease inhibitor). The column was washed
with buffer A and eluted with a stepwise gradient of imidazole (50,
Table 1. Primers used in this study.
Primer Sequence (59 to 39)
BCG aspS-pMV261 forward GATCGATCGGATCCAGTGTTTGTGCTGCGCAGCCACGCC
BCG aspS-pMV261 reverse GATCGATCAAGCTTCTATTTATTCACACTCGGGTGCGAC
M. smegmatis aspS-pMV261 forward GATCGATCGGATCCAGTGCTGCGCACTCATGCCGCCGG
M. smegmatis aspS-pMV261 reverse GATCGATCAAGCTTTCACGCCTTTGACTTGGCGTCTTC
M. tuberculosis aspS-pET28b forward GATCGATCCATATGTTTGTGCTGCGCAGCCAC
M. tuberculosis aspS-pET28b reverse GATCGATCAAGCTTTGCCTGCTGGACCCGCTTG
M. smegmatis aspS-pET28b forward GATCGATCCATATGCTGCGCACTCATGCCGCC
M. smegmatis aspS-pET28b reverse GATCGATCAAGCTTCGCCTTTGACTTGGCGTC
doi:10.1371/journal.pone.0113568.t001
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75, 100, 250 and 500 mM) in Buffer A. The purified fractions
were analysed by SDS-PAGE and the relevant fractions contain-
ing Mt-AspS were pooled and dialysed against Buffer B (20 mM
Tris-HCl pH 8.0, 50 mM NaCl, 10% glycerol, 1 mM DTT and
100 mM EDTA) and concentrated with an Amicon ultrafiltration
unit containing a 10 kDa cut off membrane. Protein concentration
was measured with the BCA protein reagent kit using BSA as a
standard.
Mt-AspS in vitro activity assay
The tRNA-independent pyrophosphate exchange assay, as
described previously [43,44] was adapted to a 96-well microtitre
plate format, for monitoring the reactions. ADPNP + L-Asp R
AMP-Asp + PNP and AMP-Asp + PPi R ATP + L-Asp. The
AspS activity assays were performed in triplicate at 37uC for
30 minutes. The assay was modified from that reported previously
[44] as follows: the reaction mixture for the Mt-AspS assay was in
a final assay volume of 200 ml containing 20 mM HEPES pH 7.6,
4 mM MgCl2, 50 mM KCl, 1 mM DTT, 2 mM ADPCP or
3 mM ADPNP, 10 mM D-glucose, 0.5 mM NADP+, 10 mM L-
Asp, 3 mg of yeast hexokinase and L. mesenteroides glucose-6-
phophate dehydrogenase mixture, 6 mg of Mt-AspS and 250 mM
of pyrophosphate. Using 96-well Costar 3603 black plates with a
clear bottom, the assay was initiated by the addition of
pyrophosphate using the injector in the plate reader. The plates
were shaken for a few seconds and absorbance was measured at
340 nm with a Pherastar FS microtitre plate reader (BMG
Labtech). Initial reaction rates for each substrate (i.e. ADPNP or
ADPCP or L-Asp or PPi) were measured at 10 to 12 different
substrate concentrations, while keeping the other two substrates at
a fixed saturating concentration. KM values were determined by
non-linear least square fitting of Michaelis-Menten curves and
expressed as mean +/2 standard error of mean. Assays were
repeated in 96-well Greiner flat bottom black plates, measuring
fluorescence intensity with excitation and emission wavelength of
350 and 450 nm, respectively. The Mt-AspS kinetic data was
analysed using Mars software and exported to Excel with graphs
generated using graphPad prism version 5.
Hexokinase/Glucose-6-phosphate dehydrogenase (HK/
G6P-DH) coupled assay
Hexokinase phosphorylates glucose to glucose-6-phosphate,
which in turn is coupled to glucose-6-phosphate dehydrogenase,
which oxidises glucose-6-phosphate to gluconate-6-phosphate in
the presence of the cofactor NADP+. The reaction mixture
consisted of 20 mM Hepes pH 7.6, 4 mM MgCl2, 1 mM DTT,
0.1 mM ATP, 50 mM KCl, 0.5 mM NADP+, 10 mM glucose and
120 ng of yeast hexokinase and L. mesenteroides glucose-6-
phophate dehydrogenase mixture in a total volume of 200 ml.
The ATP concentration was varied from 20 to 450 mM to
determine the KM for ATP. The reaction was initiated with D-
glucose and the rate of reduction of NADP+ to NADPH was
measured in the absorbance mode at 340 nm and assays were
performed in triplicate.
IC50 determination of compound 1 and 2
The IC50 dose response assays for 1 and 2 were done at the
apparent KM of ADPCP and L-Asp, 24 mg of Mt-AspS and
250 mM PPi. All compounds were dissolved in DMSO. In the
maximum (100% activity) and minimum (0% activity) controls
similar volumes of DMSO were added instead of compounds 1
and 2. DMSO was used previously at a concentration of 10% to
screen a library of compounds in a tRNA-independent assay of
aminoacyl tRNA synthetases, and CHAPS had been used at 1.5%
in the MurM enzymatic assay [45]. The highest concentration of
DMSO and CHAPS used in the Mt-AspS assay were 10% (v/v)
and 1.5% (w/v), respectively. Different concentrations of 1 and 2
were aliquoted initially into the wells of a microtitre plate followed
by the reaction mixture and the reaction initiated with PPi and
read in the fluorescence mode using Pherastar. The controls were
run with Mt-AspS (Maximum) and without Mt-AspS (Minimum)
for each compound. Percentage activity was calculated using the
formula: [Activity of enzyme with test compound – Minimum/
Maximum-Minimum]6 100, where Maximum is the activity in
the presence of enzyme, substrates and cofactors, numerator
Minimum is the activity in the presence of substrates, cofactors and
test compound but without enzyme and denominator Minimum is
the background activity in the presence of substrates and cofactors
but without enzyme. IC50 was defined as the concentration
resulting in 50% inhibition of enzymatic activity. The dose
response curves of the inhibitors were plotted as the percentage
activity versus the log concentration of the inhibitor and the IC50
values were determined using non-linear regression function in
GraphPad Prism.
X-ray crystallographic structure determination of M.
smegmatis AspS (Ms-AspS)
Prior to setting up crystallisation experiments, protein was
dialysed into 20 mM Tris-HCl pH 8.0, 50 mM NaCl, 10%
glycerol, 100 mM EDTA and 1 mM DTT and concentrated by
ultrafiltration. Crystals of Ms-AspS were obtained by vapour
diffusion in 96-well sitting drop plates (SwissSci), using a Mosquito
liquid handler (TTP Labtech) to pipette droplets of 100 nl Ms-
AspS (25 mg/ml) +100 nl reservoir solution. Initial crystals were
obtained from commercial sparse matrix screens (Molecular
Dimensions) grown over a reservoir of 30% (v/v) pentaerythritol
ethoxylate, 0.1 M magnesium formate, 0.1 M Tris-HCl, pH 8.5.
Crystals were briefly immersed in reservoir solution complemented
with 15% glycerol for cryoprotection, mounted in nylon loops and
flash frozen in liquid nitrogen. X-ray diffraction data was recorded
on a MicroMax 007HF X-ray generator equipped with a Saturn
944 CCD detector (Rigaku), integrated and scaled using XDS,
XSCALE [46]. Initial phases were obtained by molecular
replacement (PHASER, search model pdb entry 1C0A) [47].
The model was rebuilt and refined [48,49]. Coordinates and
structure factors for Ms-AspS are deposited in the Protein Data
Bank (www.rcsb.org).
In silico methods
Prior to docking, the M. smegmatis AspS crystal structure was
refined applying Prime preparation and refinement tools of the
Protein preparation wizard implemented in the Schro¨dinger
software package. After the addition of hydrogens and detection
of disulfide bonds the structure was optimized by applying default
parameters of the Impref utility using the OPLS2001 force field.
The maximum allowed root-mean-square deviation between the
refined structure and the input crystal structure was 0.3. The same
refinement protocol was applied to the D174N and T565I point
mutant AspS structures following mutation of the respective
residue. The ligand structure was prepared using the LigPrep
utility at pH7.4. For docking runs the Induced Fit method [50]
implemented in the Schro¨dinger software was applied, combining
the Glide docking method combined with Prime structural
refinement tools to account for the flexibility of protein side
chains within 5 A˚ of the ligand during docking. Induced Fit
settings were at default values except the size of the box that
encloses the targeted site was set to 22 A˚ and extra-precision mode
Characterization of Mycobacterial AspS, a Promising TB Drug Target
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was selected. In the Induced Fit workflow the initial Glide docking
run used softened potentials (Van der Waals scaling of 0.50),
followed by refinement of the structures applying Prime side chain
optimization of residues within 5 A˚ from docked ligand poses. The
derived ‘induced-fit’ receptor structures were then utilized for the
final step of Glide re-docking with default parameters, applied to
structures within 30 kcal/mol of the lowest energy structure.
Results and Discussion
Target identification and whole cell target engagement
for compound 1 and 2 against M. bovis BCG
Compound 1, which has a 4-thiazolidinone core, was identified
as an inhibitor of M. tuberculosis in a previous phenotypic screen
[26]. Resistant mutants were isolated that showed a 46-fold
increase in MIC against M. tuberculosis in comparison to the wild
type strain. WGS of three mutants identified single nucleotide
polymorphisms resulting in the substitutions at F526L and T570I
in Mt-AspS. Transfer of the F526L mutation to the parental strain
via recombineering resulted in resistance to 1, establishing whole
cell target engagement for 1. Given the anti-mycobacterial activity
of compound 1 [26], we selected this and the structurally related
compound 2 (Figure 1) for use in a detailed biochemical and
structural characterization of mycobacterial AspS. Initially, we
raised spontaneous mutants in M. bovis BCG at 106 MIC of
compound 1 (MIC = 2.6 mM), which occurred with a frequency of
46108 cells. WGS analysis of two spontaneous resistant mutants
revealed, in total, 10 high-quality single nucleotide polymorphisms
when compared to the M. bovis BCG reference sequence. Eight of
these were detected in the sequenced wild-type strain, and
therefore are likely to have arisen during laboratory storage and
passage and are unlikely to confer the resistance phenotype. The
first of two remaining single nucleotide polymorphisms was only
detected in mutant 1 at 100% allele frequency and was predicted
to result in a non-synonymous mutation in aspS (encoding an
aspartyl-tRNA synthetase), resulting in the amino acid substitution
D179N (535GAC.535AAC) (Table 2). In the second mutant
(Table 2), the only discriminatory variant present was a single
base change located 97 nucleotide bases upstream of aspS (position
2862347), likely a promoter-up mutation at the 210 consensus,
changing the sequence from 59-TGCAAT-3 to 59-TACAAT-’3.
The 59-TAXXXT-39 sequence, where X is any nucleotide, is a
highly conserved promoter region. There is 59-TG-39 one
nucleotide base upstream of the 210 motif, which could
compensate for the potentially poor wild-type promoter sequence
[51]. This promoter-up mutation would explain the resistance to
compound 1, and would be analogous to promoter mutations
observed for inhA and isoniazid resistance [52]. The differences in
the gene expression between the promoter up mutant, aspS
mutant and the wild type M. bovis BCG was determined by RT-
PCR using BCG aspS specific primers. The levels of the transcript
was higher in the promoter up mutant as opposed to wild type
BCG and the aspS mutant (Figure 2). Overexpression of M. bovis
BCG aspS and M. smegmatis aspS in M. bovis BCG resulted in
resistance against 1 and 2 (Figure 3). M. bovis BCG aspS and M.
smegmatis aspS overexpression resulted in a ten-fold and greater
than ten-fold increase in MIC (from 2.6 mM for the pMV261
strain) against 1, respectively (Figure 3). In contrast, when M.
bovis BCG aspS and M. smegmatis aspS were overexpressed, a 1.6-
fold increase in MIC (from 39.6 mM for the pMV261 strain) was
observed for 2.
Expression and purification of Mt-AspS
To generate Mt-AspS recombinant protein for HTS, the
pET28b vector was used to clone and express the C-terminally
His6-tagged Mt-AspS. The resulting protein was purified from the
soluble fraction by a single-step Ni2+ chelate affinity chromatog-
raphy procedure and gave a single band on SDS-PAGE. The yield
of the purified protein was 6 mg per litre of culture and the
enzyme preparation was stable when stored at 280uC for up to six
weeks.
Mt-AspS and hexokinase/glucose-6-phosphate
dehydrogenase in vitro activity assays
The tRNA-independent assays, monitoring either the fluores-
cence or absorbance signals, revealed Michaelis-Menten kinetics,
displaying the prototypical hyperbolic saturation curve (Fig-
ure 4A–E) for the substrates ADPCP and ADPNP, as well as
the co-substrates L-Asp and PPi, with KM values as reported in
Table 3. Mt-AspS could utilise both ADPCP and ADPNP as
substrates in the presence of the co-substrate L-Asp. The apparent
KM for ADPNP (1077674.83 mM) in the absorbance mode was
3.5 times higher than that for ADPCP (300.8612.29 mM),
indicating weaker binding of ADPNP. As expected, fluorescence
mode assays were more sensitive than absorbance mode assays,
but again ADPCP was the preferred substrate with a KM of
98.25611.23 mM, 6-fold lower than the KM for ADPNP
(604.7640.27 mM). Thus, ADPCP was a better substrate in either
assay mode and exhibited stronger binding as indicated by the
lower KM value. The KM values obtained for L-Asp using ADPCP
or ADPNP as co-substrates in the absorbance and fluorescence
mode differed only by about one standard deviation (Table 3).
We devised a hexokinase/glucose-6-phosphate dehydrogenase
(HK/G6P-DH) coupling enzyme system with the substrates to
measure the effect of 1 and 2 in the coupling enzyme system. A
specific Mt-AspS inhibitor should not inhibit the coupling
enzymes. In the fluorescence mode, it was not possible to
determine KM of ATP, since we observed quenching at high
concentrations of ATP. However, in the absorbance mode the
HK/G6P-DH assay was suited for the determination of the KM
value of ATP, which was 293.1617.10 mM as calculated form
non-linear least-squares fitting from the Michaelis-Menten plots
(Table 3 and Figure 4F).
Determination of the IC50 of inhibitors
Inhibitor studies were performed using the substrates ADPCP
and L-Asp at concentrations matching their KM values. Validation
of the Mt-AspS assay using 1 and 2, as well as in conjunction with
the HK/G6P-DH coupling enzyme activity was performed as
described in the materials and methods section. The Mt-AspS
activity was plotted against inhibitor concentration and IC50
values were determined (Figure 5). At high concentrations, both
1 and 2 showed a tendency to aggregate when added to the
aqueous reaction mixture. We therefore used the zwitterionic
detergent CHAPS at 1.5% to counter aggregation of compounds
as reported previously [53]. Both compound 1 and 2 retained
inhibitory activity at approximately three times the critical micelle
concentration (CMC) of CHAPS (CMC: 0.4920 to 0.6150%).
Compound 1 inhibited Mt-AspS activity with an IC50 of 49.9 mM
and a Hill slope of 20.9557 (R2 0.9970) and compound 2 had an
IC50 of 59.1 mM and a Hill slope of 20.9832 (R2 0.9960). Both
inhibitors turned out to be general promiscuous inhibitors and
compound 1 showed 84.3% residual activity in the HK/G6P-DH
coupling system assay at 300 mM concentration and compound 2
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showed 87.5% activity at 100 mM concentration and exhibited
steep dose response curves.
Compound aggregates are known to disrupt bacterial mem-
branes and are responsible for inhibiting many enzymes at higher
concentrations but could have biological activities at lower
concentrations [54–56]. MIC values reported recently for
compound 1 against M. tuberculosis mc2 7000 were 0.7 mM in
liquid media and approximately 18-fold higher (12.5 mM) in solid
media [26]. Promiscuous compounds tend to be associated with a
logP of 2.5 to 3 [57]. Indeed, with a logP value of 2.99, compound
1 falls within the logP-range of promiscuous compounds [26].
Crystal structure of apo Ms-AspS and mapping of the
inhibitor binding site
To aid future hit-to-lead medicinal chemistry efforts, we
determined the crystal structure of Ms-AspS by molecular
replacement, refining the model to a resolution of 2.4 A˚ (Table 4).
As the closely related aspartyl tRNA synthase AspRS from E. coli
[51], Ms-AspS forms a dimer (Figure 6A). In the context of the
crystal lattice, the two monomers are related by crystal symmetry
burying an extensive dimer interface from solvent. The tertiary
structure is conserved across species boundaries, with a 3-domain
architecture consisting of the N-terminal, b-barrel like domain, a
central catalytic domain and an insertion domain that is spliced
into the sequence of the catalytic domain (Figure 7). The
superposition with the tRNA-bound structure of E. coli AspRS
(Figure 6B) illustrates the close structural relationship between
the two enzymes (48% sequence identity). Despite the fact that the
Ms-AspS enzyme was crystallised without tRNA, the orientation of
the N-terminal domain, which mediates anticodon recognition,
and the insertion domain, which contributes to positioning the
tRNA in the active site pocket, relative to the catalytic domain
barely changes (Figure 6B). In the vicinity of the active site, Ms-
AspS includes an extended flexible loop encompassing residues
429 to 441 (Figure 6C). The corresponding loop in E. coli AspRS
is 11 amino acid residues shorter (Figure 7). An apo-structure of
Ms-AspS has recently been deposited in the PDB (entry 4O2D), in
which this loop assumes a very different conformation, forming a
2-turn a-helix and folding back onto the aspartyl adenylate
binding site. The differential conformation likely occurs due to
differences in crystal packing constraints. The two coordinate sets
have different space group symmetry (P212121 and C2221,
respectively), and in the present structure, the conformation of
the 429–441 loop is constrained by forming contacts with a
symmetry-related copy of MsAspS. In contrast, the packing
environment in 4O2D imposes no direct constraints on the
conformation of this loop.
We mapped the location of mutations conferring resistance,
reported previously [26] and generated here, to 1 on the present
structure. When considered in the context of the Ms-AspS dimer,
the three resistance mutations are in close proximity of each other,
surrounding a narrow pocket that opens to the aspartyl adenylate
binding site in the catalytic domain (Figure 8). Thr565 (M.
tuberculosis Thr570) is contributed by the opposing monomer and
sits at the bottom of the pocket. Asp174 (M. tuberculosis Asp179)
lines the side of the pocket, while Phe521 (M. tuberculosis Phe526)
forms close contacts with residues that do line the pocket.
Using Induced Fit docking protocols we docked compound 1
into this pocket (Figure 9). The obtained docked pose predicts a
number of favorable non-polar and polar contacts with residues
lining the pocket as follows. The piperidine ring in compound 1
participates in non-polar interactions with P169 while the
thiazolidinone moiety forms aromatic interactions with F514.
The dichlorophenyl ring has non-polar/steric contacts with a
number of residues: F451, L517, L199, F196, as well as T565 from
the adjacent subunit. The side chain of T565 is in close proximity
Table 2. Single nucleotide polymorphisms detected in M. bovis BCG spontaneous resistant mutants.
M. bovis BCG chromosomea Wild-type allele
Predicted amino
acid change Region Spontaneous resistant mutants
1.1.1.1. Mutant 1 1.1.1.2. Mutant 2
2861716 Gac D179N aspS AacT Gac-
2862347 1.1.1.3. 1.1.1 1.1.1.4. n/a- Upstream of aspS 1.1.1.5. G- 1.1.1.6. A
aGenomic positions are relative to M. bovis BCG str. Pasteur 1173P2 chromosome (Genbank accession: NC_008769.1). Mutations are reported relative to aspS which is
encoded on the reverse strand.
doi:10.1371/journal.pone.0113568.t002
Figure 2. Comparison of the expression levels of the transcript produced by wild typeM. bovis BCG, aspSmutant 1 and promoter up
mutant 2 by RT-PCR. RT-PCR was performed with RT (upper panel) and without RT (lower panel). The RT-PCR cycling conditions were programmed
for 25, 30, 40 and 50 cycles, respectively, to get sufficient yields of the 200 bp amplified product and analysed on a 2% agarose gel following staining.
doi:10.1371/journal.pone.0113568.g002
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of the ligand’s phenyl ring (the closest ring carbon is at 3.8 A˚ from
the threonine side chain methyl). Guided by the resistance
conferring mutation sites that include this threonine, we generated
the T565I AspS mutant structure in silico and attempted to re-
dock compound 1 using the same protocols, however, no
successfully docked poses could be obtained, consistently with
the results of the resistant mutations study. Another resistance
conferring mutant site corresponds to D174 which is the residue
predicted to form hydrogen bonding interactions with the amide
group of compound 1 (Figure 9). Re-docking compound 1 into
the D174N mutant AspS structure resulted in a different
positioning of the piperidine-amide that has no direct interaction
with residue 174 (not shown). In this pose the distance between the
amide groups of the N174 side chain and compound 1 is 8.3 A˚.
Thus, docked poses of compound 1 at the D174N mutant and the
wild type M. smegmatis AspS structure are consistent with this
residue being an important contributor to the binding of
compound 1 at AspS. The docking hypothesis of compound 1
at the AspS crystal structure predicts several favorable polar
contacts also, as follows. In addition to hydrogen bonding with
D174, the amide group of compound 1 forms hydrogen bonding
interactions with S167 and the backbone carbonyl of A172. The
carbonyl of the thiazolidinone participates in hydrogen binding
with T168 while the 2-chlorine substituent on the phenyl forms
polar interactions with T165 and the backbone amine of R166.
While F521 is not directly accessible to bound ligands, it is possible
that the resistance-conferring mutation of F521 to Leu induces
conformational changes that propagate to the proposed pocket.
While we attempted to generate crystals of Ms-AspS bound to 1
and 2, we could not overcome poor solubility in the crystallization
buffers. In the absence of co-crystallized ligand, the proposed
docked pose of compound 1 provides a plausible model of its Asp-
bound structure with a number of favorable polar and non-polar
contacts as described here.
Conclusion
The phenotypic antitubercular activity of the 4-thiazolidinones
has been known for several years based on PubChem deposition of
HTS results for several libraries totaling over 300,000 compounds
against virulent M. tuberculosis [7–9]. In a continuation of our
work to identify targets of interesting and novel active samples
from the TAACF screens, we were pursuing a TAACF active 1, a
member of the 4-thiazolidinones. We reasoned that compounds
active against the whole bacillus in vitro would offer advantages
for hit-to-lead development, as they are already active against the
Figure 3. Whole cell target based resistance using overexpression of aspS in M. bovis BCG against compound 1 and 2. The
overexpression plasmids pMV261, pMV261-BCG aspS and pMV261-Ms aspS were electroporated into M. bovis BCG with kanamycin at 25 mg/ml, and
the MIC and resistance against compound 1 and 2 was evaluated.
doi:10.1371/journal.pone.0113568.g003
Characterization of Mycobacterial AspS, a Promising TB Drug Target
PLOS ONE | www.plosone.org 7 November 2014 | Volume 9 | Issue 11 | e113568
bacterium in vitro. Starting with scaffolds that show antibacterial
activity offers significant advantages over pure target-based
optimization programs in that optimization starts from the
privileged position of proven whole-cell antibacterial activity
[11]. Nevertheless, before initiating a rational drug discovery
and optimization program it is crucial to identify a putative target
Table 3. Summary of Km determined for the Mt-AspS substrates and the hexokinase/glucose-6-phosphate dehydrogenase
substrate.
AspS assay KM - absorbance mode
Varied substrate Unvaried substrate KM (mM) Correlation coefficient R2
ADPCP (30–2000 mM) L-Asp (10 mM) and PPi (250 mM) 300.8612.29 0.9949
L-Asp (100–1000 mM) ADPCP (2 mM) and PPi (250 mM) 168.3612.14 0.9669
PPi (2.5–1000 mM) ADPCP (2 mM) and L-Asp (2 mM) 33.8562.743 0.9842
ADPNP (50–4000 mM) L-Asp (10 mM) and PPi (250 mM) 1077674.83 0.9887
L-Asp (100–10000 mM) ADPNP (3 mM) and PPi (250 mM) 363.7633.63 0.9685
Hexokinase/Glucose-6-P dehydrogenase assay KM - absorbance mode
Varied substrate Unvaried substrate KM (mM) Correlation coefficient R2
ATP (20–450 mM) Glucose (10 mM) and NADP+ (500 mM) 293.1617.10 0.9948
AspS assay KM - fluorescence mode
Varied substrate Unvaried substrate KM (mM) Correlation coefficient R2
ADPCP (7.5–1000 mM) L-Asp (10 mM) and PPi (250 mM) 98.25611.23 0.9544
L-Asp (25–5000 mM) ADPCP (1 mM) and PPi (250 mM) 143.4618.83 0.9450
PPi (2.5–1000 mM) ADPCP (1 mM) and L-Asp (1.5 mM) 76.42610.10 0.9648
ADPNP (25–2500 mM) L-Asp (10 mM) and PPi (250 mM) 604.7640.27 0.9912
L-Asp (25–5000 mM) ADPNP (2.4 mM) and PPi (250 mM) 332.8641.63 0.9478
doi:10.1371/journal.pone.0113568.t003
Figure 4. Substrate dependence of Mt-AspS activity. Michaelis-Menten curves were fitted for A) varying ADPCP as substrate. B) L-Asp as
substrate at fixed saturating concentrations of ADPCP and PPi. C) PPi as substrate at fixed concentrations of ADPCP and L-Asp. D) ADPNP as
substrate. E) L-Asp as substrate at fixed concentrations of ADPNP and PPi. F) ATP dependence of hexokinase/glucose-6-phosphate dehydrogenase
activity. The initial velocity data (dA/min) were plotted against the substrate concentration. Each assay was done in triplicate and expressed as mean
6 standard error of mean.
doi:10.1371/journal.pone.0113568.g004
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Figure 5. Dose response in vitro activity curves of the effect of compound 1 (A) and compound 2 (B) on Mt-AspS. The reaction mixture
was added to increasing amounts of 1 and 2, and the reaction initiated with the substrate PPi and the fluorescence intensity read using a microtitre
plate reader. The assays were performed in triplicate and the percentage activity plotted versus the log mM concentration of 1 and 2.
doi:10.1371/journal.pone.0113568.g005
Table 4. Statistics of X-ray diffraction data and crystallographic structure refinement.
X-ray diffraction data
Crystal Ms-AspS
X-ray source Rigaku MM007HF
Wavelength (A˚) 1.5418
Space group C2221
Cell parameters a,b,c (A˚) 71.6, 141.5, 156.8
Molecules per asymmetric unit 1
Resolution, last shell (A˚) 42.04–2.40 (2.53–2.40)
Rmerge (%)
1 12.5 (65.4)
Total, unique observations 518,021, 31,382
I/s(I)1 25.1 (5.1)
Completeness (%)1 99.7 (98.3)
Multiplicity1 16.5 (15.6)
Refinement
Resolution range (A˚) 78.41–2.40
Unique reflections used 29,771
Rcryst, Rfree (%) 21.5, 24.6
Number of non-hydrogen atoms 4,456
Protein 4,320
Solvent 136
RMSD bonds (A˚) 0.007
RMDS angles (u) 1.2
B-factors
Wilson B-factor (A˚2) 38.8
Overall average (A˚2) 34.1
Protein average (A˚2) 34.4
Solvent average (A˚2) 23.5
RMSD B-factors 0.8
Ramachandran plot2
Favoured region (%) 96.5
Allowed regions (%) 3.5
Disallowed (number) 0
1Numbers in parentheses refer to the last shell. 2Ramachandran statistics were determined using Molprobity [62].
doi:10.1371/journal.pone.0113568.t004
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as well as a crystal structure of that target. A recent publication has
identified a potential target as M. tuberculosis aspartyl-tRNA
synthetase AspS for analog 1 [26]. Our work with both 1 and 2
further validate AspS as the putative target of the 4-thiazolidi-
nones. Furthermore, we have solved the apo-structure of the target
and developed a binding model for this inhibitor class that should
help produce more rationally designed inhibitors to improve
binding and inhibition. For example, it is interesting to note that 1
is a superior inhibitor to compound 2 although the differences are
relatively modest. As well as being a better inhibitor, possibly due
to specific hydrogen bonding of the carboxamide in the active site,
1 should be more hydrolytically stable than 2 (a carboxamide
versus a carboxylic acid ethyl ester). In fact, it is likely that
hydrolysis of the ester to the free –COOH might significantly alter
protein binding and inhibition due to the neighboring aspartic
acid residue (Asp174/Asp179) lining the proposed ligand binding
site, potentially leading to charge-charge clashes. These possibil-
ities suggest new analogs that might optimize favorable charge-
charge interactions in the protein, and we are currently working
on new analogs to improve solubility and binding with the goal of
obtaining better inhibitors that might allow co-crystallization. It
should be pointed out, however that both 1 and 2 fall into
thiazolidinone or rhodanine class that are broadly considered Pan
Assay INterference compounds or PAINS as they show up as
promiscuously active in numerous HTS assays and are notoriously
difficult to optimize against screening targets [58]. In fact, there is
a general move to eliminate the class from screening libraries and
proscribe reports of these compounds as assay hits in the literature
[58,59] in spite of the fact that several known drugs are based on
the scaffold that include ralitoline, etozoline, pioglitazone and
thiazolidomycin [60]. Our data reported herein support the likely
specific activity of compounds 1 and 2 against AspS as resistant
mutants arose specifically to this protein at a specific locale in the
target identified. Typically, broadly acting, promiscuous com-
pounds that have numerous targets do not support target
identification via generation of resistant mutants since target cells
are unable to generate effective multiple target mutations that
bypass blockades against several targets. When resistance does
Figure 6. Structure of M. smegmatis AspS. A) Dimer of Ms-AspS in ribbon representation (colored by monomer) with resistance-conferring
mutation sites indicated in yellow spheres. The binding site of aspartyl adenylate (AMO, spheres in cyan) is derived from the secondary structure-
matched superposition with the structure of E. coli AspRS (PDB entry 1C0A, [61]). B) Superposition of the Ms-AspS monomer with the tRNA-bound
structure E. coli AspRS (grey ribbon, PDB entry 1C0A). C) Detail of the superposition of Ms-AspS (blue ribbon), PDB entry 4O2D (green ribbon) of the
same protein and E. coli AspRS (grey ribbon), focusing on the flexible loop spanning residues 427 to 444. To illustrate the variable conformation of the
loop, sticks indicate the spatial positions of Trp444 and Asp436.
doi:10.1371/journal.pone.0113568.g006
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arise to these types of compounds, it typically comes via entry and
exit proteins either by restricting drug access or active efflux of the
agent. From these (PAINS) compounds we have identified a
druggable protein target via specific mutations, produced a crystal
structure and binding model, and developed a HTS assay for
further screening of diverse chemical libraries. Hence, at least in
the case of 1 and 2 useful information and research has accrued
speaking to their value as chemical probes. We would also note,
Figure 7. Alignment of the amino acid sequences of AspS of M. smegmatis (Msm), M. tuberculosis (Mtb) and M. bovis (Mbv) with that
of E. coli AspRS (Eco). Bars in blue, green and orange indicate the N-terminal, catalytic and insertion domains of AspS, respectively. Asterisks
indicate the sites of resistance-conferring mutations.
doi:10.1371/journal.pone.0113568.g007
Characterization of Mycobacterial AspS, a Promising TB Drug Target
PLOS ONE | www.plosone.org 11 November 2014 | Volume 9 | Issue 11 | e113568
Figure 8. Molecular surface of Ms-AspS showing the inhibitor-binding pocket adjacent to the aspartyl adenylate binding site,
showing the position of the aspartyl adenylate donor substrate relative to the proposed pocket. The sites of resistance conferring
mutations are indicated by spheres in yellow, and the aspartyl adenylate donor substrate (AMO), positioned according to the superposition with E.
coli AspRS (PDB entry 1C0A, [61]) is indicated by spheres in turquoise.
doi:10.1371/journal.pone.0113568.g008
Figure 9. Induced Fit docked pose of compound 1 at the M. smegmatis AspS crystal structure. Only amino acids forming direct
interactions with compound 1 are shown. Carbon atoms of AspS are colored light green except for carbons of resistance conferring mutant site
residues, which are colored purple. Carbons of compound 1 are shown in orange; all other atoms are colored by atom type (Oxygen red, Nitrogen
blue, Sulphur yellow, Chlorine dark green, Hydrogen white). Labels of residues participating in polar interactions are colored brown, labels of all other
residues are in black. Polar interactions are indicated with dashed lines and are numbered. Distances between heavy atoms of the atoms groups
participating in polar interactions are as follows: 1. 3.1 A˚; 2. 3.8 A˚; 3. 3.0 A˚; 4. 3.2 A˚; 5. 3.1 A˚; 6. 3.7 A˚.
doi:10.1371/journal.pone.0113568.g009
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however, that future research and screening in an in vitro Mt-
AspS and HK/G6p-DH assay developed through this work and
adapted to a 96 well plate format suitable for HTS screening of
compound libraries will be utilized to identify alternative,
improved scaffolds that pass PAINS filters and are suitable for
hit-to-lead medicinal chemistry programmes to generate more
soluble and target specific inhibitors.
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